Final top-line results expected Q4 2020 PRINCETON, N.J., June 24, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in… Read More..

New York, New York--(Newsfile Corp. - June 23, 2020) - As the United States enters nearly its fifth month in the global fight against COVID-19, many investors have set their eyes on companies racing to discover a cure and restore things back to a sense of normalcy. But despite this… Read More..

Poster presentation of pharmacodynamic and safety data of cavrotolimod (AST-008) from Exicure’s ongoing Phase 1b/2 clinical trial in solid tumor patients Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is presenting updated pharmacodynamic and safety data at the American Association… Read More..